Clinical trials: Glial Tumor
Brain and Central Nervous System Tumors
Capecitabine and Radiation Therapy in Treating Young Patients With Newly Diagnosed, Nonmetastatic Brain Stem Glioma or High-Grade Glioma
RATIONALE: Drugs used in chemotherapy, such as capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00357253
- Testing
- capecitabine, radiation therapy
- Where
- 12 sites in United States
- Volunteers
- 24 people
- Sponsor
- Pediatric Brain Tumor Consortium
Brain and Central Nervous System Tumors
Carmustine in Treating Patients With Progressive or Recurrent Glioblastoma Multiforme
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase II trial to study the effectiveness of carmustine in treating patients who have progressive or…
- Trial name
- NCT00006656
- Testing
- carmustine in ethanol, conventional surgery
- Where
- 12 sites in United States
- Sponsor
- Direct Therapeutics
Low Grade Glioma of Brain
Surgical Management of Low Grade Glioma
To assess the morbidity and mortality in low grade glioma patients following surgical management.
- Trial name
- NCT06499922
- Testing
- SURGICAL EXCISION
- Volunteers
- 100 people
- Sponsor
- Assiut University
Glioblastoma
Cerebral Connectivity and Metabolic Phenotype of Gliomas: Prospective Addition of DTI and Rs-fMRI to a Preoperative FDG PET Strategy, With Neuropsychological Correlates and Post-treatment Follow-up
The aim of this study is to determine whether the diffuse cerebral metabolic disturbances observed in glioblastoma are exclusively linked to the direct and indirect effects of tumor infiltration (particularly structural…
- Trial name
- GlioConnect (NCT07628257)
- Testing
- 18F-FDG PET/MRI with additional DTI and rs-fMRI sequences
- Where
- France
- Volunteers
- 80 people
- Sponsor
- Centre Paul Strauss
Refractory Brain Tumors
Antineoplaston Therapy in Treating Patients With Brain Tumors
RATIONALE: Current therapies for adults with persistent or recurrent brain tumors provide very limited benefit to the patient. The anti-cancer properties of Antineoplaston therapy suggest that it may prove beneficial in the…
- Trial name
- NCT00003457
- Testing
- Antineoplaston therapy (Atengenal + Astugenal)
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Burzynski Research Institute
Glioblastoma
Memantine for Recurrent Glioblastoma
The purpose of this study is to determine if a medication called memantine is effective in treating glioblastoma. Memantine targets a specific receptor, called a glutamate receptor, which is thought to be involved in the growth…
- Trial name
- NCT01260467
- Testing
- memantine
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Rochester
Glioblastoma
Immunotherapy Targeted Against Cytomegalovirus in Patients With Newly-Diagnosed WHO Grade IV Unmethylated Glioma
This single-arm phase II study will assess the impact of tetanus pre-conditioning and adjuvant Granulocyte Macrophage Colony Stimulating Factor (GM-CSF) on overall survival of patients newly diagnosed with World Health…
- Trial name
- I-ATTAC (NCT03927222)
- Testing
- Human CMV pp65-LAMP mRNA-pulsed autologous DCs containing GM CSF, Temozolomide, Tetanus-Diphtheria Toxoid (Td)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Mustafa Khasraw, MBChB, MD, FRCP, FRACP
Glioblastoma IDH (Isocitrate Dehydrogenase) Wildtype
The GLIOMAX Study: MT027 Allogeneic CAR-T for Recurrent Glioma
This is a Phase II trial to evaluate the safety, tolerability, efficacy, and PK/ pharmacodynamic profiles of MT027 injected via ICV in participants with recurrent or progressive IDH-wildtype glioblastoma (WHO 2021 CNS Grade 4)…
- Trial name
- GLIOMAX-101 (NCT07386002)
- Testing
- Intracerebroventricular injection of MT027 UCAR-T Cell targeting B7H3
- Where
- 4 sites in United States, Taiwan
- Volunteers
- 40 people
- Sponsor
- T-MAXIMUM Pharmaceutical Inc
Medulloblastoma, Medulloblastoma, Childhood
Individualized Treatment Plan in Children and Young Adults With Relapsed Medulloblastoma and Ependymoma
The current study will use a new treatment approach based on the molecular characteristics of each participant's tumor. The study will test the feasibility in the pilot phase of performing real-time drug screening on tissue taken…
- Conditions
- Medulloblastoma, Medulloblastoma, Childhood, Medulloblastoma Recurrent, Ependymoma
- Trial name
- PNOC027 (NCT05057702)
- Testing
- Specialized Tumor Board Treatment Plan, Combinations
- Where
- 9 sites in United States
- Volunteers
- 74 people
- Sponsor
- University of California, San Francisco
Brain and Central Nervous System Tumors, Neuroblastoma
Radiolabeled MAB Therapy in Patients With Refractory, Recurrent, or Advanced CNS or Leptomeningeal Cancer
The purpose of this study is to test the feasibility and toxicity of administering intrathecal immunotherapy for patients with central nervous system/leptomeningeal (CNS/LM) malignancies.
- Conditions
- Brain and Central Nervous System Tumors, Neuroblastoma, Sarcoma
- Trial name
- NCT00089245
- Testing
- Iodine I 131 MOAB 8H9
- Where
- United States
- Volunteers
- 177 people
- Sponsor
- Y-mAbs Therapeutics
Glioblastoma
CM93 Treatment in Subjects With Epidermal Growth Factor Receptor (EGFR)-Modified Recurrent Glioblastoma (rGBM)
This is a first-in-human study of CM93, an oral investigational drug, in adults with Epidermal Growth Factor Receptor-modified glioblastoma.
- Trial name
- NCT04933422
- Testing
- CM93
- Volunteers
- 72 people
- Sponsor
- Crimson Biopharm Inc.
Glioblastoma
A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose and the recommended Phase 2 dose of ivonescimab that can be given to patients who have recurrent glioblastoma.
- Trial name
- NCT06672575
- Testing
- Ivonescimab
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- M.D. Anderson Cancer Center
Life-limiting Illness, Breast Cancer
Therapeutic Support to Strengthen Dignity, Mental Well-being and Quality of Life in Acute Palliative Care Patients.
The goal of this clinical trial is to test the benefit of a newly designed personalized therapeutic intervention compared to the standard specialized palliative care service at the swiss acute palliative hospital care.The main…
- Conditions
- Life-limiting Illness, Breast Cancer, Glioblastoma, Prostate Cancer
- Trial name
- NCT06549075
- Testing
- Therapeutic support, Standard Specialized Palliative Consultation Service
- Where
- Switzerland
- Volunteers
- 42 people
- Sponsor
- University Hospital, Basel, Switzerland
Glioblastoma
Predicting Response Patterns to Treatment in Glioblastoma (GBM) Patients
PROPHETIC GBM - Predicting response patterns to treatment in Glioblastoma (GBM) oncology patients based on host response evaluation during anti-cancer treatments
- Trial name
- PROPHETIC (NCT04219475)
- Where
- 4 sites in Israel
- Volunteers
- 1,000 people
- Sponsor
- OncoHost Ltd.
Glioma
Construction and Application of an IDH Mutation-Targeted PET/MRI Imaging Framework for Precision Diagnosis of Gliomas
Glioma is the most common primary intracranial tumor in adults, with high-grade gliomas accounting for more than 50% of all gliomas and having the highest mortality rate.
- Trial name
- NCT07405372
- Testing
- Targeted IDH PET/MRI
- Where
- China
- Volunteers
- 10 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration
A Trial of Dabrafenib, Trametinib and Hydroxychloroquine for Patients With Recurrent LGG or HGG With a BRAF Aberration
This phase I/II trial is designed to study the side effects, best dose and efficacy of adding hydroxychloroquine to dabrafenib and/or trametinib in children with low grade or high grade brain tumors previously treated with…
- Conditions
- Low Grade Glioma (LGG) of Brain With BRAF Aberration, High Grade Glioma (HGG) of the Brain With BRAF Aberration, Low Grade Glioma of Brain With Neurofibromatosis Type 1
- Trial name
- NCT04201457
- Testing
- Dabrafenib, Trametinib, Hydroxychloroquine
- Where
- 15 sites in United States
- Volunteers
- 57 people
- Sponsor
- Pediatric Brain Tumor Consortium
Glioma
ExAblate Blood Brain Barrier Disruption (BBBD) for Planned Surgery in Suspected Infiltrating Glioma
This study is designed to assess the safety and feasibility of using the ExAblate, Type 2 to temporarily disrupt the blood brain barrier in non-enhancing suspected infiltrating glioma.
- Trial name
- NCT03322813
- Testing
- ExAblate 4000 - Type 2
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- InSightec
Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor
Pazopanib Hydrochloride in Treating Young Patients With Solid Tumors That Have Relapsed or Not Responded to Treatment
This phase I trial is studying the side effects and best dose of pazopanib hydrochloride in treating young patients with solid tumors that have relapsed or not responded to treatment.
- Conditions
- Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Embryonal Tumor, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma
- Trial name
- NCT00929903
- Testing
- pazopanib hydrochloride, pharmacological study
- Where
- 14 sites in United States
- Volunteers
- 55 people
- Sponsor
- National Cancer Institute (NCI)
High Grade Glioma, Diffuse Intrinsic Pontine Glioma
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
The goal of this study is to determine the efficacy of the 1) ribociclib and everolimus to treat pediatric and young adult patients newly diagnosed with a high-grade glioma (HGG), including DIPG, that have genetic changes in…
- Conditions
- High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Anaplastic Astrocytoma, Glioblastoma
- Trial name
- NCT05843253
- Testing
- Ribociclib, Everolimus, Temozolomide (TMZ)
- Where
- 20 sites in United States, Australia and 4 more
- Volunteers
- 120 people
- Sponsor
- Nationwide Children's Hospital
Glioma, Neoplasms
Study on Neuroepithelial Tumor Grading and Pseudoprogression After Glioma Therapy Using Advanced Functional MRI Techniques
Contrast-enhanced MRI is the most common way for evaluating neuroepithelial tumor grading and monitoring for tumor recurrence,but the ability to predict tumor behavior remains very limited.In this study, the investigators will…
- Trial name
- NCT02622620
- Volunteers
- 86 people
- Sponsor
- Tang-Du Hospital
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.